ClinicalTrials.Veeva

Menu

Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain

A

All India Institute Of Medical Science (AIIMS)

Status

Unknown

Conditions

Cancer Pain
Cancer, Oropharynx
Pain, Intractable

Treatments

Procedure: 10% lignocaine injection
Procedure: 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection

Study type

Interventional

Funder types

Other

Identifiers

NCT04085120
IEC-402/07.06.2019, RP-34/2019

Details and patient eligibility

About

The study will compare the efficacy and safety of Ropivacaine/dexamethasone vs 10% lignocaine injection in distal glossopharyngeal nerve block for intractable cancer pain

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with proven carcinoma of the oropharynx and supraglottic larynx with estimated survival of 3 months or more.
  • Pain lasting for at least 2 weeks with an average intensity of 5 or more on an 11-point numeric rating scale (NRS) refractory to a combination strong opioids and NSAIDS

Exclusion criteria

  1. Local infection or skin ulceration at the puncture site
  2. Local anaesthetic allergy
  3. Psychiatric illness that affected cooperation.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

60 participants in 2 patient groups

Ropivacaine/dexamethasone group
Experimental group
Description:
3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
Treatment:
Procedure: 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
10% lignocaine injection group
Experimental group
Description:
4 ml of 10% lignocaine
Treatment:
Procedure: 10% lignocaine injection

Trial contacts and locations

1

Loading...

Central trial contact

Dinesh Manoharan, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems